
Patients with diabetic erectile dysfunction (DMED) are not satisfied with the effects of first‐line phosphodiesterase type 5 inhibitors (PDE5Is). Hence, this article was designed to mine hub biomarkers in DMED and explore its potential mechanisms. This study identified Sparc, Lox, Srebf1, and Mmp3 as potential hub biomarkers in the SD rats DMED model for future drug development and found its significant associations with m6A regulators and ferroptosis, but not with immunity or cuproptosis.
Like
Save
Share